Altria, Pfizer, Healthpeak, and Verizon offer investors a dual-threat strategy, combining share price growth that beats the S&P 500 with dividend yields north of 5.2%.
Altria (MO) is highlighted for its dual-benefit profile, having outperformed the S&P 500's 12.9% year-to-date gain while maintaining a dividend yield exceeding 5.2%. This combination of capital appreciation and income generation positions the stock as an attractive option for investors seeking both growth and yield.
It offers both capital growth, having outperformed the S&P 500 YTD, and a high dividend yield of over 5.2%.
Pfizer (PFE) is recognized as one of the four S&P 500 stocks delivering both significant price gains and high income. By exceeding the 12.9% year-to-date benchmark return while offering a yield above 5.2%, the company provides a defensive yet growth-oriented investment case.
PFE has outperformed the S&P 500's 12.9% year-to-date gain while providing a dividend yield of over 5.2%.
Verizon (VZ) is featured for its ability to provide investors with both capital gains and substantial income. With share price growth exceeding the S&P 500's 12.9% year-to-date performance and a dividend yield above 5.2%, it serves as a core holding for income-focused portfolios seeking growth.
It is both, as it has delivered double-digit percentage gains YTD while offering a dividend yield of over 5.2%.
Altria, Pfizer, Healthpeak Properties, and Verizon are delivering a rare combination of double-digit capital appreciation and high income. Each stock has outperformed the S&P 500's 12.9% year-to-date gain while maintaining dividend yields exceeding 5.2%.
These stocks are achieving the rare feat of delivering double-digit share price growth that exceeds the S&P 500 while simultaneously offering high dividend yields above 5.2%.